{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:51:28Z","timestamp":1790869888395,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103549"],"award-info":[{"award-number":["82103549"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Fundation of Fujian Provinc","award":["2021J05147"],"award-info":[{"award-number":["2021J05147"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gallbladder cancer (GBC) is known for its high malignancy and multidrug resistance. Previously, we uncovered that impaired integrity and stability of the elongator complex leads to GBC chemotherapy resistance, but whether its restoration can be an efficient therapeutic strategy for GBC remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RT-qPCR, MS-qPCR and ChIP-qPCR were used to evaluate the direct association between ELP5 transcription and DNA methylation in tumour and non-tumour tissues of GBC. EMSA, chromatin accessibility assays, and luciferase assays were utilized to analysis the DNA methylation in interfering PAX5-DNA interactions. The functional experiments in vitro and in vivo were performed to investigate the effects of DNA demethylating agent decitabine (DAC) on the transcription activation of elongator complex and the enhanced sensitivity of gemcitabine in GBC cells. Tissue microarray contains GBC tumour tissues was used to evaluate the association between the expression of ELP5, DNMT3A and PAX5.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrated that transcriptional repression of ELP5 in GBC was highly correlated with hypermethylation of the promoter. Mechanistically, epigenetic analysis revealed that DNA methyltransferase DNMT3A-catalysed hypermethylation blocked transcription factor PAX5 activation of ELP5 by disrupting PAX5-DNA interaction, resulting in repressed ELP5 transcription. Pharmacologically, the DNA demethylating agent DAC eliminated the hypermethylated CpG dinucleotides in the ELP5 promoter and then facilitated PAX5 binding and reactivated ELP5 transcription, leading to\u00a0the enhanced function of the elongator complex. To target this mechanism, we employed a sequential combination therapy of DAC and gemcitabine to sensitize GBC cells to gemcitabine-therapy through epigenetic activation of the elongator complex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that ELP5 expression in GBC is controlled by DNA methylation-sensitive induction of PAX5. The sequential combination therapy of DAC and gemcitabine could be an efficient therapeutic strategy to overcome chemotherapy resistance in GBC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-021-02186-0","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T08:08:19Z","timestamp":1637827699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy"],"prefix":"10.1186","volume":"40","author":[{"given":"Sunwang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"2186_CR1","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"2186_CR2","first-page":"CD011746","volume":"4","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746.","journal-title":"Cochrane Database Syst Rev"},{"key":"2186_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"2186_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na'ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55\u201368.","journal-title":"Drug Resist Updat"},{"key":"2186_CR5","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1038\/s41467-019-13420-x","volume":"10","author":"S Xu","year":"2019","unstructured":"Xu S, Zhan M, Jiang C, He M, Yang L, Shen H, et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun. 2019;10:5492.","journal-title":"Nat Commun"},{"key":"2186_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nsmb.2234","volume":"19","author":"S Glatt","year":"2012","unstructured":"Glatt S, Letoquart J, Faux C, Taylor NM, Seraphin B, Muller CW. The Elongator subcomplex Elp456 is a hexameric RecA-like ATPase. Nat Struct Mol Biol. 2012;19:314\u201320.","journal-title":"Nat Struct Mol Biol"},{"key":"2186_CR7","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1084\/jem.20142288","volume":"212","author":"A Ladang","year":"2015","unstructured":"Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, et al. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine. J Exp Med. 2015;212:2057\u201375.","journal-title":"J Exp Med"},{"key":"2186_CR8","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1084\/jem.20160397","volume":"213","author":"S Delaunay","year":"2016","unstructured":"Delaunay S, Rapino F, Tharun L, Zhou Z, Heukamp L, Termathe M, et al. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J Exp Med. 2016;213:2503\u201323.","journal-title":"J Exp Med"},{"key":"2186_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0243-7","volume":"558","author":"F Rapino","year":"2018","unstructured":"Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605\u20139.","journal-title":"Nature."},{"key":"2186_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrg.2016.13","volume":"17","author":"AP Feinberg","year":"2016","unstructured":"Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284\u201399.","journal-title":"Nat Rev Genet"},{"key":"2186_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25:403\u201318.","journal-title":"Nat Med"},{"key":"2186_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","volume":"25","author":"S Saghafinia","year":"2018","unstructured":"Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G. Pan-cancer landscape of aberrant DNA methylation across human tumors. Cell Rep. 2018;25:1066\u201380.e1068.","journal-title":"Cell Rep"},{"key":"2186_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","journal-title":"Signal Transduct Target Ther"},{"key":"2186_CR14","doi-asserted-by":"publisher","first-page":"348ra397","DOI":"10.1126\/scitranslmed.aaf3124","volume":"8","author":"Y Liu","year":"2016","unstructured":"Liu Y, Zheng X, Yu Q, Wang H, Tan F, Zhu Q, et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med. 2016;8:348ra397.","journal-title":"Sci Transl Med"},{"key":"2186_CR15","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1038\/s41388-019-0799-1","volume":"38","author":"M Wu","year":"2019","unstructured":"Wu M, Sheng L, Cheng M, Zhang H, Jiang Y, Lin S, et al. Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. Oncogene. 2019;38:5425\u201339.","journal-title":"Oncogene."},{"key":"2186_CR16","doi-asserted-by":"publisher","first-page":"W170","DOI":"10.1093\/nar\/gkn294","volume":"36","author":"Y Kumaki","year":"2008","unstructured":"Kumaki Y, Oda M, Okano M. QUMA: quantification tool for methylation analysis. Nucleic Acids Res. 2008;36:W170\u20135.","journal-title":"Nucleic Acids Res"},{"key":"2186_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1023\/B:BILE.0000044922.43572.2d","volume":"26","author":"MW Chan","year":"2004","unstructured":"Chan MW, Chu ES, To KF, Leung WK. Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection. Biotechnol Lett. 2004;26:1289\u201393.","journal-title":"Biotechnol Lett"},{"key":"2186_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature07643","volume":"458","author":"S Leidel","year":"2009","unstructured":"Leidel S, Pedrioli PGA, Bucher T, Brost R, Costanzo M, Schmidt A, et al. Ubiquitin-related modifier Urm1 acts as a Sulphur carrier in thiolation of eukaryotic transfer RNA. Nature. 2009;458:228\u201332.","journal-title":"Nature."},{"key":"2186_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.stem.2018.07.018","volume":"23","author":"J Sun","year":"2018","unstructured":"Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, et al. SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. Cell Stem Cell. 2018;23:355\u201369.e359.","journal-title":"Cell Stem Cell"},{"key":"2186_CR20","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.4049\/jimmunol.167.8.4494","volume":"167","author":"S Rao","year":"2001","unstructured":"Rao S, Procko E, Shannon MF. Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J Immunol. 2001;167:4494\u2013503.","journal-title":"J Immunol"},{"key":"2186_CR21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","volume":"18","author":"LC Li","year":"2002","unstructured":"Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427\u201331.","journal-title":"Bioinformatics."},{"key":"2186_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051803","volume":"22","author":"Y Li","year":"2021","unstructured":"Li Y, Chen X, Lu C. The interplay between DNA and histone methylation: molecular mechanisms and disease implications. EMBO Rep. 2021;22:e51803.","journal-title":"EMBO Rep"},{"key":"2186_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/bioinformatics\/18.2.333","volume":"18","author":"X Messeguer","year":"2002","unstructured":"Messeguer X, Escudero R, Farr\u00e9 D, N\u00fa\u00f1ez O, Mart\u00ednez J, Alb\u00e0 MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18:333\u20134.","journal-title":"Bioinformatics."},{"key":"2186_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.semcdb.2015.07.007","volume":"44","author":"A Mayran","year":"2015","unstructured":"Mayran A, Pelletier A, Drouin J. Pax factors in transcription and epigenetic remodelling. Semin Cell Dev Biol. 2015;44:135\u201344.","journal-title":"Semin Cell Dev Biol"},{"key":"2186_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1101\/gr.257576.119","volume":"30","author":"M Cusack","year":"2020","unstructured":"Cusack M, King HW, Spingardi P, Kessler BM, Klose RJ, Kriaucionis S. Distinct contributions of DNA methylation and histone acetylation to the genomic occupancy of transcription factors. Genome Res. 2020;30:1393\u2013406.","journal-title":"Genome Res"},{"key":"2186_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature16462","volume":"528","author":"S Domcke","year":"2015","unstructured":"Domcke S, Bardet AF, Adrian Ginno P, Hartl D, Burger L, Sch\u00fcbeler D. Competition between DNA methylation and transcription factors determines binding of NRF1. Nature. 2015;528:575\u20139.","journal-title":"Nature."},{"key":"2186_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026948","volume":"7","author":"T Sato","year":"2017","unstructured":"Sato T, Issa JJ, Kropf P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med. 2017;7:a026948.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2186_CR28","doi-asserted-by":"publisher","first-page":"32535","DOI":"10.1074\/jbc.M112.402727","volume":"287","author":"P Close","year":"2012","unstructured":"Close P, Gillard M, Ladang A, Jiang Z, Papuga J, Hawkes N, et al. DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator. J Biol Chem. 2012;287:32535\u201345.","journal-title":"J Biol Chem"},{"key":"2186_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5:230.","journal-title":"Signal Transduct Target Ther."},{"key":"2186_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2186_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872\u20136.","journal-title":"Nat Genet"},{"key":"2186_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68:959\u201369.","journal-title":"J Hepatol"},{"key":"2186_CR33","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/hep.31585","volume":"73","author":"J Br\u00e4gelmann","year":"2021","unstructured":"Br\u00e4gelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, et al. Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer. Hepatology. 2021;73:2293\u2013310.","journal-title":"Hepatology."},{"key":"2186_CR34","doi-asserted-by":"publisher","first-page":"14687","DOI":"10.1007\/s13277-016-5355-9","volume":"37","author":"P Sharma","year":"2016","unstructured":"Sharma P, Bhunia S, Poojary SS, Tekcham DS, Barbhuiya MA, Gupta S, et al. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease. Tumour Biol. 2016;37:14687\u201399.","journal-title":"Tumour Biol"},{"key":"2186_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mc.20457","volume":"48","author":"P Garc\u00eda","year":"2009","unstructured":"Garc\u00eda P, Manterola C, Araya JC, Villaseca M, Guzm\u00e1n P, Sanhueza A, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. 2009;48:79\u201389.","journal-title":"Mol Carcinog"},{"key":"2186_CR36","doi-asserted-by":"publisher","first-page":"eaaj2239","DOI":"10.1126\/science.aaj2239","volume":"356","author":"Y Yin","year":"2017","unstructured":"Yin Y, Morgunova E, Jolma A, Kaasinen E, Sahu B, Khund-Sayeed S, et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science. 2017;356:eaaj2239.","journal-title":"Science."},{"key":"2186_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrc1778","volume":"6","author":"EJ Robson","year":"2006","unstructured":"Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006;6:52\u201362.","journal-title":"Nat Rev Cancer"},{"key":"2186_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479\u201383.","journal-title":"Nature."},{"key":"2186_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296\u2013307.","journal-title":"Nat Genet"},{"key":"2186_CR40","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226\u201331.","journal-title":"Nat Genet"},{"key":"2186_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.15252\/embj.201695495","volume":"36","author":"L Smeenk","year":"2017","unstructured":"Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. EMBO J. 2017;36:718\u201335.","journal-title":"EMBO J"},{"key":"2186_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hep.24124","volume":"53","author":"W Liu","year":"2011","unstructured":"Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G, et al. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology. 2011;53:843\u201353.","journal-title":"Hepatology."},{"key":"2186_CR43","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/onc.2011.511","volume":"31","author":"X Li","year":"2012","unstructured":"Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY, et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene. 2012;31:3419\u201330.","journal-title":"Oncogene."},{"key":"2186_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/15592294.2017.1365207","volume":"12","author":"K Kurimoto","year":"2017","unstructured":"Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, et al. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma. Epigenetics. 2017;12:865\u201374.","journal-title":"Epigenetics."},{"key":"2186_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32:71\u201387.e77.","journal-title":"Cancer Cell"},{"key":"2186_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204.","journal-title":"Mol Cell"},{"key":"2186_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11010-014-2143-y","volume":"396","author":"D Wang","year":"2014","unstructured":"Wang D, Yang PN, Chen J, Zhou XY, Liu QJ, Li HJ, et al. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma. Mol Cell Biochem. 2014;396:67\u201377.","journal-title":"Mol Cell Biochem"},{"key":"2186_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13073-015-0225-4","volume":"7","author":"S Voisin","year":"2015","unstructured":"Voisin S, Alm\u00e9n MS, Zheleznyakova GY, Lundberg L, Zarei S, Castillo S, et al. Many obesity-associated SNPs strongly associate with DNA methylation changes at proximal promoters and enhancers. Genome Med. 2015;7:103.","journal-title":"Genome Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02186-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T06:15:45Z","timestamp":1675923345000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02186-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committees of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and the written informed consent was obtained from all subjects in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}